跳至主要内容
临床试验/NCT02236728
NCT02236728已完成不适用

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP)

Boehringer Ingelheim0 个研究点目标入组 497 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
497
主要终点
Assessment of Parkinson's disease characteristics

研究概览

简要总结

The primary objective of this study was to describe neurologists' population of patients treated with pramipexole and suffering from Parkinson's disease (so called 'primary care' population).

The secondary objectives were:

  • Evaluate the mean dose of pramipexole prescribed under actual conditions of use depending on the severity of the disease.
  • Evaluate the reasons for choosing pramipexole as treatment.
  • Identify the patient profiles determining the choice of dose of pramipexole prescribed

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients suffering from idiopathic Parkinson's Disease and treated with pramipexole for at least two months, examined in consultation

排除标准

  • Patient refusing to take part
  • Patient taking part in a clinical trial

研究组 & 干预措施

Parkinson's disease patients

干预措施: Pramipexole (Drug)

结局指标

主要结局

Assessment of Parkinson's disease characteristics

时间窗: 9 months

Assessment of Patient's demographic characteristics

时间窗: 9 months

次要结局

  • Description of the actual treatments of PD(9 months)
  • Evaluation for reasons for choosing pramipexole as treatment(9 months)
  • Assessment of Severity of the Parkinson Disease (PD)(9 months)
  • Assessment of Disease Stage Stage according to Hoehn and Yahr and Unified Parkinson Disease Rating Scale III (UPDRS III) scores(9 months)
  • Evaluation of the state of health perceived by the patient using the questionnaire EQ-5D(9 months)
  • Number of patients with adverse events(9 months)
  • Assessment of Treatment history(9 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Observational Study in Parkinson's Disease of the... | 临床试验